Financing momentum Vascular Therapies has recently closed a private financing round totaling $25 million in March 2022, with overall funding reaching $90 million. This indicates strong investor confidence and potential leverage for partnerships, collaborations, or milestone-driven deals aligned with their Sirogen program.

Clinical stage The company is a clinical-stage biopharma focused on intraoperative local perivascular drug delivery to reduce surgical stenosis in vascular access for kidney disease patients. This emphasizes opportunities for early adopters in surgical centers and health systems tracking innovative perioperative solutions.

Lead program Sirogen is the core asset, a proprietary sirolimus formulation for local delivery to prevent stenosis during vascular access surgery. Potential sales angles include collaborations with vascular surgeons, dialysis centers, and hospital systems seeking improved AV fistula outcomes.

Market positioning With revenue in the low single digits to mid single digits and a niche focus on kidney disease vascular access, there is room to pursue strategic partnerships with large device and pharma players serving nephrology and interventional vascular care.

Strategic outreach Key executive hires in leadership historically signal growth and commercialization readiness. Engage at early planning stages with clinical trial conduits, key opinion leaders, and hospital procurement teams to align on trial sites, reimbursement considerations, and post-trial adoption routes.